NCT02608684View on ClinicalTrials.gov

A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 8, 2016

Primary Completion Date

May 17, 2019

Study Completion Date

March 7, 2022

Conditions

Ovarian Cancer

Interventions

DRUG

Pembrolizumab

Pembrolizumab IV solution

DRUG

Gemcitabine

Gemcitabine IV solution

DRUG

Cisplatin

Cisplatin IV solution

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Cedars-Sinai Medical Center

OTHER

NCT02608684 - A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer | Biotech Hunter | Biotech Hunter